RVNC News and Press, Revance Therapeutics Inc. From 08/07/23

2023-08-07 11:20:35 ET Major earnings expected before the bell on Tuesday include: Duke Energy ( DUK ) Barrick Gold ( GOLD ) Medical Properties Trust ( MPW ) Organon ( OGN ) United Parcel Service ( UPS ) For further details see: Notable ea...

Conference Call Scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conf...

2023-07-30 11:23:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund® (the Fund) appreciated 3.58% (Institutional Shares) in the ...

2023-07-03 15:50:36 ET Summary FDA approval of Revance Therapeutics, Inc.'s DAXXIFY for glabellar lines in the U.S. achieved; Initial launch brought in revenues of $15.4 million. A supplemental Biologics Licensing Application of DAXXIFY for adults with cervical dystonia has been a...

2023-06-29 14:51:32 ET Summary Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical data compared to established competitor Botox, agg...

2023-05-09 21:23:03 ET Revance Therapeutics, Inc. (RVNC) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Jessica Serra – Investor Relations Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Sc...

2023-05-09 16:48:12 ET Revance Therapeutics press release ( NASDAQ: RVNC ): Q1 GAAP EPS of -$0.74. Revenue of $49.3M (+95.2% Y/Y). Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%.- Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and...

- Q1 total revenue of $49.3 million, a YoY increase of 95.3%. - Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%. - Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch. - FDA approves Ajinomoto Biopharma Services, Revance’...

2023-05-09 13:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Discovery Fund® (the Fund) was up 11.20% compared...

Conference Call Scheduled for Tuesday, May 9, 2023 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding conference ...